REBLOZYL Drug Profile

« Back to Dashboard

Summary for Tradename: REBLOZYL

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for REBLOZYL

Recent Clinical Trials for REBLOZYL

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
EuroBloodNet Association	PHASE2
Bristol-Myers Squibb	Phase 3
Bristol-Myers Squibb	Phase 2

See all REBLOZYL clinical trials

Pharmacology for REBLOZYL

Physiological Effect	Increased Erythroid Cell Production
Established Pharmacologic Class	Erythroid Maturation Agent

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for REBLOZYL Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for REBLOZYL Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for REBLOZYL Derived from Patent Text Search

No patents found based on company disclosures

Reblozyl Market Dynamics and Financial Trajectory: Luspatercept Sales, Competition, Exclusivity, and Patent Risk

Last updated: October 31, 2026

Reblozyl, the brand name for luspatercept-aamt, has become one of Bristol Myers Squibb's fastest-growing hematology products. Global sales increased from roughly $0.7 billion in 2022 to approximately $1.0 billion in 2023, driven by expanded use in lower-risk myelodysplastic syndromes and continued demand in beta thalassemia. The principal commercial opportunity is broader first-line adoption in anemia associated with lower-risk MDS. The main risks are competing anemia therapies, payer controls, biosimilar timing after the 12-year biologic exclusivity period, and dependence on a relatively concentrated hematology market.

What is Reblozyl and how does it work?

Reblozyl is a recombinant fusion protein that binds selected transforming growth factor beta superfamily ligands. It enhances late-stage erythroid maturation and increases red blood cell production.

The product is administered by subcutaneous injection, generally every three weeks. Its approved uses are concentrated in chronic anemia associated with hematologic disorders:

Indication	U.S. regulatory milestone	Commercial relevance
Anemia in adults with beta thalassemia requiring regular red blood cell transfusions	FDA approval, November 2019	Established the initial commercial market
Anemia in adults with very low- to intermediate-risk MDS with ring sideroblasts who had an inadequate response to, or are unlikely to respond to, erythropoiesis-stimulating agents	FDA approval, April 2020	Expanded the product into MDS
Anemia in adults with very low- to intermediate-risk MDS who may require regular red blood cell transfusions and are erythropoiesis-stimulating agent naive	FDA approval, August 2023	Expanded use toward earlier-line treatment

The 2023 MDS expansion is strategically important because ESA-naive patients represent an earlier and larger treatment segment than patients who have already failed an ESA. FDA approval was supported by the COMMANDS trial, which showed superior transfusion independence and hemoglobin response versus epoetin alfa in selected lower-risk MDS patients. [1]

How much revenue does Reblozyl generate?

Bristol Myers Squibb reports Reblozyl revenue as part of its product portfolio following the 2021 acquisition of Acceleron Pharma. The acquisition gave BMS full ownership of the product and its commercial economics.

Fiscal year	Approximate global Reblozyl sales	Financial interpretation
2021	About $0.4 billion	Partial-year impact after BMS acquired Acceleron
2022	About $0.7 billion	Continued uptake in MDS and beta thalassemia
2023	About $1.0 billion	Strong growth before and after the broader MDS approval
2024 onward	Growth-dependent on MDS conversion and international expansion	Requires wider earlier-line adoption to sustain high growth

The 2023 result represented growth of roughly 40% over 2022 on a rounded basis. Reblozyl has moved from a specialty hematology product into a material BMS growth asset, although it remains much smaller than Eliquis, Opdivo, or other major BMS products.

BMS's financial exposure is increasing because the company acquired Acceleron for approximately $11.5 billion in cash. Reblozyl is the central commercial asset supporting the transaction. The product must therefore sustain multiyear growth to justify the acquisition price and offset patent losses affecting older BMS medicines.

What drives Reblozyl market growth?

The primary growth driver is the expansion from ESA-experienced MDS patients into ESA-naive patients.

Lower-risk MDS is the main growth engine

MDS is a group of bone marrow disorders that can produce chronic anemia, transfusion dependence, iron overload, and progressive disease. Lower-risk MDS patients often remain in treatment for extended periods, which gives successful anemia therapies recurring revenue potential.

The commercial opportunity depends on four factors:

1. Increasing use before ESA failure.
2. Reduction in transfusion burden.
3. Physician adoption of the COMMANDS data.
4. Reimbursement for a relatively high-cost injectable biologic.

Reblozyl's strongest positioning is in patients for whom raising hemoglobin and reducing transfusions are more clinically meaningful than simply delaying disease progression.

Beta thalassemia provides a stable base

Beta thalassemia patients who require regular transfusions have chronic treatment needs. Reblozyl can reduce transfusion requirements in some patients, which supports recurring demand. The market is smaller than the potential lower-risk MDS market, but patient treatment duration and specialist concentration support commercial predictability.

International expansion remains available

The product has been marketed in multiple jurisdictions, including the United States and European markets. International growth depends on country-level reimbursement, local treatment guidelines, transfusion practices, and regulatory approvals. The commercial model is more complex outside the United States because national health systems may restrict use to patients with defined transfusion burdens or inadequate ESA response.

How does Reblozyl compare with competing anemia treatments?

Reblozyl competes with established therapies and emerging agents rather than with a single direct substitute.

Therapy	Main use in the relevant market	Competitive position
Epoetin alfa and darbepoetin alfa	Earlier-line anemia treatment, particularly in MDS	Low-cost and established; Reblozyl competes directly in ESA-naive MDS
Red blood cell transfusions	Supportive treatment	Remains necessary for many patients; Reblozyl competes by reducing transfusion dependence
Lenalidomide	Lower-risk MDS with del(5q) abnormalities	Strong genotype-specific option
Imetelstat	Lower-risk MDS after inadequate response to or loss of response to ESAs	FDA-approved in 2024; adds a later-line competitor
Iron chelation therapy	Management of transfusional iron overload	Complementary rather than directly substitutive
Investigational erythroid and hepcidin-pathway therapies	MDS and thalassemia development programs	Longer-term competitive risk

Imetelstat is the most important recent competitive development in MDS. Its approval for certain lower-risk MDS patients after ESA failure creates a competing option in the later-line setting, but it does not immediately displace Reblozyl's strategic position in ESA-naive patients. [2]

What is the FDA exclusivity timeline for Reblozyl?

Reblozyl is a biologic licensed under the Public Health Service Act. The reference product receives 12 years of FDA biologic reference-product exclusivity from the date of first licensure.

Regulatory protection	Relevant date
First U.S. approval	November 8, 2019
Four-year biosimilar application restriction	November 8, 2023
Twelve-year reference-product exclusivity	November 8, 2031
Potential pediatric extension	Could add six months if applicable and earned

The 12-year period does not prevent all competitors from developing a biosimilar before 2031. It prevents FDA approval of a biosimilar until the exclusivity period expires. A biosimilar applicant could have filed after the four-year restriction ended, subject to the statutory pathway and patent disclosures.

Orphan-drug exclusivity may apply to particular indications. The original beta thalassemia and MDS approvals were associated with orphan-drug designations, but orphan exclusivity is indication-specific and does not function as a complete product-wide substitute for biologic reference-product exclusivity. [3]

What patents protect Reblozyl?

Reblozyl is protected by a patent estate covering the luspatercept molecule, activin-receptor ligand trapping, pharmaceutical compositions, formulations, and therapeutic uses. The relevant rights originated with Acceleron and transferred to BMS after the acquisition.

The commercially important patent categories are:

• Modified activin receptor type IIB polypeptides.
• Fusion proteins and ligand-trap constructs.
• Use of luspatercept for anemia and ineffective erythropoiesis.
• Formulations and dosage forms.
• Manufacturing and recombinant protein production methods.

Public patent records indicate protection extending into the 2030s for key molecule and use claims, but the effective market-entry date depends on patent validity, patent-term adjustment, patent-term extension, and the scope of any biosimilar applicant's litigation settlement. The biologic exclusivity date of November 2031 is therefore the clearest baseline for U.S. biosimilar timing. Patent expiry dates should not be treated as a single product-wide date because individual claims expire on different schedules.

Unlike small-molecule medicines, Reblozyl does not have a conventional FDA Orange Book listing. Biologic patent and exclusivity analysis is conducted through the Purple Book framework, FDA biologic records, USPTO records, and litigation filings. [4]

Has Reblozyl faced Paragraph IV challenges or patent litigation?

Paragraph IV certification is a Hatch-Waxman mechanism for small-molecule ANDA products. Reblozyl is a biologic, so a conventional Paragraph IV challenge is not the expected legal pathway.

A future luspatercept biosimilar applicant would use the Biologics Price Competition and Innovation Act process. That process includes patent-information exchanges, potential patent litigation, and FDA approval timing governed by reference-product exclusivity. The litigation sequence can differ from Hatch-Waxman cases because the biosimilar applicant may participate in the statutory patent dance or provide notice of commercial marketing.

Through the publicly available regulatory and company disclosures used for this analysis, no major Reblozyl biosimilar litigation had materially changed the U.S. launch timeline before the 2031 reference-product exclusivity endpoint.

How strong is the Reblozyl patent estate?

The estate is commercially meaningful but not immune to challenge.

Its strengths are:

• A biologic with a complex recombinant structure.
• Manufacturing know-how that may be difficult to replicate.
• Multiple patent categories rather than a single composition claim.
• Regulatory exclusivity through 2031.
• Established clinical use across MDS and beta thalassemia.
• Potentially differentiated dosing and patient-selection claims.

Its weaknesses are:

• Biosimilar applicants can challenge patents individually.
• Method-of-use claims may be narrower than composition claims.
• Some patents may expire before the 12-year biologic exclusivity period ends.
• Clinical differentiation may weaken if competing agents show better transfusion outcomes or broader eligibility.
• Manufacturing patents may be designed around even when the core molecule is difficult to reproduce.

The most defensible commercial protection comes from the combination of biologic exclusivity, clinical adoption, physician familiarity, manufacturing complexity, and reimbursement positioning.

Which companies are challenging Reblozyl commercially?

The competitive set includes established pharmaceutical companies and specialist hematology developers.

• Janssen and Geron compete through imetelstat in lower-risk MDS.
• Amgen and other manufacturers compete through ESAs and supportive-care products.
• Novartis and generic manufacturers compete in selected MDS subgroups through established treatments.
• Regional and global biosimilar companies may pursue luspatercept after the statutory pathway becomes commercially attractive.

No approved biosimilar had materially disrupted Reblozyl's U.S. market as of the latest period covered here. The most immediate competitive risk is therapeutic substitution within MDS, not biosimilar erosion.

What generic or biosimilar launch risks exist?

The probability of U.S. biosimilar entry before November 2031 is low because FDA reference-product exclusivity blocks approval until that date. Entry after 2031 depends on patent litigation and settlement terms.

A plausible launch sequence is:

Period	Market event
2023-2026	Biosimilar development and possible patent challenges
2027-2030	Patent litigation, licensing, and settlement negotiations
November 2031	Earliest end of 12-year reference-product exclusivity
2031 onward	Potential FDA approval and commercial launch, subject to patents
Post-launch	Gradual erosion because biologics typically decline more slowly than small molecules

The erosion profile may be moderate rather than immediate. Reblozyl is administered by specialists, requires clinical monitoring, and may be selected based on patient response. Hospital and payer contracting could accelerate substitution, while physician familiarity and manufacturing complexity could slow it.

What licensing deals affect Reblozyl?

Reblozyl originated with Acceleron and was commercialized through a collaboration with Celgene. Bristol Myers Squibb acquired Acceleron in 2021, bringing the product and associated rights under BMS control. The acquisition replaced the prior collaboration structure with direct BMS ownership.

The transaction has two financial implications:

1. BMS retains the full economic upside from future Reblozyl sales.
2. BMS also assumes development, manufacturing, regulatory, and lifecycle-management costs.

The product's value is therefore linked to both revenue growth and the ability to extend use across MDS subgroups, geographic markets, and potentially additional anemia indications.

What is the outlook for Reblozyl revenue?

The base-case financial outlook is continued growth through the second half of the 2020s, with the 2023 ESA-naive MDS approval providing the largest near-term expansion opportunity.

Revenue upside depends on:

• Conversion of ESA-naive MDS patients.
• Higher duration of treatment.
• Increased use before transfusion dependence becomes severe.
• International reimbursement.
• Additional label expansion.
• Stable pricing despite payer scrutiny.

Revenue downside depends on:

• Slower physician adoption of COMMANDS data.
• Payer preference for low-cost ESAs.
• Competition from imetelstat and future MDS agents.
• Safety or tolerability concerns.
• A narrower-than-expected eligible patient population.
• Patent settlements that allow early biosimilar entry.

Reblozyl is unlikely to become a product of Eliquis scale. It can, however, remain a multibillion-dollar hematology asset if BMS converts a meaningful share of earlier-line MDS treatment and maintains its position in beta thalassemia.

Key Takeaways

• Reblozyl is BMS's principal erythroid-maturation product and a major post-acquisition growth asset.
• Global sales increased from approximately $0.7 billion in 2022 to about $1.0 billion in 2023.
• The 2023 FDA approval for ESA-naive lower-risk MDS materially expanded the addressable market.
• Reblozyl has 12-year U.S. biologic reference-product exclusivity through November 8, 2031.
• The product is governed by the Purple Book framework rather than a conventional Orange Book listing.
• Imetelstat is the most important recent competitive threat, while ESAs remain the largest practical substitute.
• Biosimilar erosion is unlikely to affect the U.S. market before 2031, subject to patent litigation and settlement outcomes.
• The strongest financial case depends on earlier-line MDS adoption, treatment duration, and international reimbursement.

FAQs

When will Reblozyl lose U.S. market exclusivity?

The FDA's 12-year reference-product exclusivity is scheduled to expire on November 8, 2031. Patent rights may delay biosimilar launch beyond that date.

Is Reblozyl listed in the Orange Book?

No. Reblozyl is a biologic, so its regulatory exclusivity and patent information are evaluated through the Purple Book and related FDA and USPTO records.

Is Reblozyl a biosimilar or a reference biologic?

Reblozyl is the reference biologic for luspatercept-aamt. A future luspatercept biosimilar would use the BPCIA pathway.

What disease generates most Reblozyl growth?

Lower-risk MDS is the main expansion opportunity, especially after the 2023 approval for ESA-naive patients. Beta thalassemia provides an established recurring market.

Can Reblozyl replace blood transfusions?

Reblozyl can reduce transfusion requirements in some patients, but it does not eliminate the need for transfusions in all patients and is not a universal substitute for supportive care.

References

1. U.S. Food and Drug Administration. (2023). FDA approves luspatercept-aamt for anemia in adults with lower-risk myelodysplastic syndromes. FDA.

2. U.S. Food and Drug Administration. (2024). FDA approves imetelstat for myelodysplastic syndromes. FDA.

3. U.S. Food and Drug Administration. (2019). Reblozyl prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

5. Bristol Myers Squibb. (2024). 2023 annual report. Bristol Myers Squibb.

6. Bristol Myers Squibb. (2021). Bristol Myers Squibb completes acquisition of Acceleron Pharma Inc. Bristol Myers Squibb.

7. Celgene Corporation. (2019). Celgene and Acceleron announce FDA approval of Reblozyl for anemia in adults with beta thalassemia. Celgene Corporation.